MedTrace Logo

Shen Hai Long Capsule for Male Asthenospermia

NCT05745610 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2023-02-27

No results posted yet for this study

Summary

To evaluate the efficacy and safety of Shen Hai Long Capsule in the treatment of mild to moderate asthenospermia in men.

Conditions

  • Efficacy and Safety of Shen Hai Long Capsule for Mild to Moderate Asthenospermia in Men

Interventions

DRUG

Shen Hai Long Capsule

3 times/day (9 capsules/day) for 12 weeks

DRUG

Sheng Jing Capsule

3 times/day (12 capsules/day) for 12 weeks

Sponsors & Collaborators

  • Zhongnan Hospital

    lead OTHER

Principal Investigators

  • Yuanzhen Zhang, Prof. · Wuhan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
22 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-15
Primary Completion
2024-06-30
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05745610 on ClinicalTrials.gov